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Introduction

Salt

The concept of ethical treatment of human subjects has a long and constantly
evolving history. Its roots are found in
ancient Anglo common law, but it was
not until the 20th century, as the abuses
inflicted on research participants came
to light, that it attained the importance it
holds today. Currently, all studies involving humans are subject to extensive
regulations, requiring the project to be
approved by an institutional review
board ORB)-a body charged with pro
tecting the patients rights while fostering valid and methodologically sound
research.’ Informed consent-the
prime component of the process by
which the patient is provided information to make a determination
as to
whether to participate in any experimental therapy or process-must
be addressed for each project. The purpose of
this paper is to address broadly issues
regarding ethics and prehospital research, focusing on informed consent.
Historical

Perspective

The history of informed consent with
respect to treatment was first commented on by Plato, who believed that
the physician should expressly not discuss care with the patient. He stated,
‘You are not healing the sick man, but
you are educating him, and he does not
want to be made a doctor but to get
we11.“2Ancient law expanded this concept, but provided minimal human
rights protection and limited the authority of the physician to treat only
those who requested it. However, on
this request, which was considered to
be implied by any person presenting to
the physician, the patient could be sub-
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PhD, RN, CS3
jected to all treatment the doctor
deemed necessary without the right to
withdraw from or even inquire about
the therapy being rendered.
Modern ethical issues have their
roots in Anglo-American common law,
which “forbid harmful or offensive nonconsensual touching, however benign
in motive or physical effect without
their consent.” Here, the first definition
of assault-a threat of approach, battery
and touching intentionally-came
into
use. The only exception was in emergency situations. The content of consent was not defined, it was interpreted
very broadly, and could take the form of
actions, words, or be implied from the
circumstances. The first case law occurred in 1914, when Supreme Court
Justice Cardoso ruled that “Every human being of adult years and sound
mind is entitled to determine what is to
be done with his own body.“3 Despite
this, ethical issues and informed consent remained poorly defined and were
left to the judgment of the researcher.
A series of horrific situations changed
all that, and brought the issues into focus, eventually leading to our current
regulations.
The first event was the revelation of
the Nazi atrocities in World War II in
the name of research uncovered during
the Nuremberg trials. This led to the
development of the Nuremberg Code in
1949, which became the cornerstone of
current research ethics.4 Five main concepts are at the heart of the code:
1. Voluntary consent by the research subject
2. Explanation of all potential hazards
3. The research produces fruitful re
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Criteria
Review

for Institutional
Board Approval

1, Risks to the patient are minimized.
2. Risks are reasonable
in relation of benefits,
including the benefit of knowledge
gained.
3. Equitable subject selection.
4. Informed
consent
sought and documented.
5. Privacy of the subjects
is maintained
strictly.
6. Ongoing
monitoring
of data to ensure safety.
7. Safeguards
are included to protect the rights and welfare of vulnerable
subjects.

sults for the good of society
4. Valid animal-model based studies
5. Each subject can stop the experiment at any time.
This code spawned a major develop
ment of case law, and while the vast majority concerned medical practice, the
rulings and principles are generally
thought to hold true for research consent. To summarize, consent deals with
the ethical principle of respect for persons. The consent process, in theory, is
supposed to ensure that the researcher
will respect the subject to be self-determining and able to make independent
free choices. Unless the person allows it,
the investigator is not allowed to violate
this tenet and touch or enter their private space. The traditional legal view of
violation of this principle and failure to
obtain adequate consent is battery.
Whether or not harm results is irrelevant. More recent case law treats failure
to obtain consent as negligence. Negligence expands on the previous legal
view and brings in the concept of standard therapy and whether the treatment
is deviating from standard therapy (as in
all experimental research). If so, then
failure to obtain proper informed consent may be treated as a negligent action. The traditional components of a
negligent action may then apply (duty,
breach, damage and casualty). In both
doctrines, the consent is held to be invalid if any information thought to be
necessary or impo~ant in the subject’s
decision-making process is withheld.
Additionally, it is incumbent on the researcher to prove the subject has
grasped the material prior to consenting.
A brief mention also should be made
concerning two further ethical codesthe Declaration of Helsinki and the
Belmont Reports<6 The thrust of the
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former is to ensure sound, ethical and
valuable research. The responsibility
for subject welfare is placed squarely on
the shoulders of the researcher. It also
recommended strict accuracy of data/
results in the publication, with a prohibition against unethical research being
published. The Belmont Report is a
more detailed analysis of basic ethical
principles for both medical practice and
research. The first deals with respect
for persons, recognizing an individual’s
right to self-determination and protecting those with diminished autonomy
through the process of informed consent. The next principle, beneficence,
strives to maximize benefit while minimizing possible risks. This is to be
guaranteed through careful, stringent,
and systematic assessment of risks and
benefits for each study. Justice, or the
principle of fairness with respect to the
distribution of benefit, as well as burden
of research, is determined through fair
selection processes that pay close attention to possible bias concerning sex,
race, societal and cultural issues.
While these developments were a
positive step in aiding ethical research
practices, the onus to ensure they were
applied properly was still left entirely to
the researcher. A series of incidents
would soon change this and bring swift
and vociferous protests from both publit and scientific communities. A succession of highly unethical studies was
publicized, the most famous of which
was the Tuskeegee Syphilis study, in
which a group of African-American
males infected with the disease continued to be observed for effects to study
the natural course of the disease, even
after treatment (penicillin) became
available.2$7 Other studies injected elderly patients with cancer cells without
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their knowledge, and intentionally exposed mentally impaired patients to
Hepatitis A.2 The concept of the benevolent researcher always striving to protect the study subjects was forever
shattered, and led to the current stringent regulations overseeing human research.
lnstit~ional

Review

Boards

In 1966, the U.S. Public Health Service
mandated that all federally funded research involving human subjects requires review by a “committee of
insti~tional associates.“1,7The mission
of this committee was to ensure that the
autonomy of the subject was respected,
that a well-defined benefit would result
from this research, and that vulnerable
subjects (e.g., children or prisoners)
would be protected. This initiated the
widespread adoption of the institutional
review board (IRB). The IRB concept
was further developed in the early 1970s
when the Public Health Service required peer review for any research sup
ported by Department
of Health
Education and Welfare grants. Subsequent to this, a series of congressional
hearings was held in 1974 and established the requirement for IRBs at all
institutions
receiving any federal
grants, and established the National
Commission for the Protection of
Human Subjects of Biomedical and
Behavioral Research. The code of federal regulations was revised in 1983 and
was adopted by the Department of
Health and Human Services (DHHS)
Office for Protection for Research Risks
(OPRR).I This set the criteria necessary
for IRB approval (Table 1). These are
general guidelines, and each IRB has
specific instructions as to the form and
content of each research proposal. This
is available from each individual IRB office. The directive also lists specific
steps on how to carry out the process of
reviewing research to ensure that it
meets the standards. It is important to
note that the IRB has been given the
right to preview all qualifying research
proposals to ensure these criteria are
met and that a valid study will result.
Institutional review boards vary in
their procedures. Most require that the
investigator submit a written proposal
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and standardized request forms for review by the committee. Although all t-e
search should be submitted through the
IRB process, some projects will be clap
sified by the IRB as minimal risk and, as
a result, receive an expedited review.
Types of research that may be classiiied
as minimal risk are chart reviews and
anonymous surveys. Although the investigator may be confident that the study
is minimal risk and, thus, does not require IRB approval, all proposals should
be submitted for review and patient
confidentiali~. This places the responsibility for the review on the IRB, minimizing investigator responsibility should
the study be inappropriately classified as
exempt from review.
The process for an expedited review
varies across institutions but often involves review by a single staff member
rather than by the entire committee.
Because an expedited review does not
involve the entire committee, the time
needed to complete the review is shortened. Investigators should determine
the time needed to obtain the appropriate IRB approval early in the planning
stages of the project.
The next step in dealing with the IRB
is to decide whether the proposed study
meets the criteria for full committee re
view. The definition of this states the IRB
has jurisdiction in “all research ~vol~ng
human subjects conducted, supported or
otherwise subject to regulation by any
federal department or agency.“1 Also, all
human-subject research performed in an
institution with written DHSS-approved
assurances applies. Put simply, any
study involvement that performs or alters any human intervention must be
IRB approved. There are also other considerations that each individual IRB may
want to review for proper confidentiality,
institutional or personal liability or other
potential problems. These regulations
concerning each particular IRB can be
obtained from the IRB office.
Suggestions for dos and don’ts when
dealing with the IRE3are listed in Table
2. The interaction between the researcher and the TRB is an involved
process. Attempts to properly interact
with the IRB members for both education and explanation purposes can yield
dramatic results and greatly improve the
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DOS and Don’ts for Interacting with the
Institutional Review Board
Do:
Design a good project
Know intricate details of the project
Show concern for protecting your patients
Use lay language in consent forms and presentation
Allow realistic time for review and modification
Know individual IRB members
Acquaint the chairperson with your protocol
Don’t:
Argue with the IRB
Submit a proposal in an improper form
Use technical language
Disregard patient rights and protection
Submit a proposal at the last minute
Be unfamiliar with any aspect of a project

project. However, this process takes
time, and it is unrealistic to believe that
each proposal will be approved on its initial submission. The investigator must
understand that the IRB has a diftlcult
job, and that board members are trying
to ensure good and proper research and
not trying to delay the project.
Air transport programs that are not associated with a single health-care organization or academic institution and have
not received federal funding may not
have an official IRB. Because of the protection offered to the researcher by the
IRB, such programs may wish to associate themselves with a sponsoring hospital or develop their own procedures for
review of proposed investigations.
Multi-center research presents additional challenges to obtaining IRB approval. The principal investigator and
project coordinator at all data collection
sites must obtain IRB approval at their
respective institutions. This requirement can create difficulties when two
IRBs have inconsistent requirements of
the investigators. A common area of difficulty lies in the consent form. Individual institutions may require specific
words to be placed in their consent
forms, and these requirements may be
in direct conflict with one another. If inconsistent consent forms are required,
the researcher may be served best by
having the subjects sign two consent
forms-the one from the institution of
the principal investigator and the one
from the insti~tion where data are be-

ing collected on that subject. Subject
consent forms may be kept at the institution where the data are collected or all
may be stored by the principal investigator. In either case, the consent forms
must be available for review by federal
or other agencies on request.
Informed

Consent

The cornerstone of each IRB proposal
and the area most scrutiniied is that of
informed consent. Without adequate
preparation and attention to this area,
the research proposal will not gain the
necessary approval from the IRB.
Absence of approp~ate informed consent also opens the researcher and the
sponsoring institution to civil liability.8
To obtain valid informed consent,
four basic tenets must be rnet.QJ,s The
first is that the subject has adequate decision-making capacity, including a
proper emotional state that allows a de
cision to be made. The patient must be
legally competent and under no coercion. Finally, all relevant information
must be disclosed in an understandable
manner to the subject. Several points
deserve explanation. Many ethicists feel
that the process of reviewing the consent with the patient is inherently
flawed, especially if a physician is participating and does not allow the subject to
make a free choice. There are many
motives for patients to participate in research one is to please the reviewer, a
factor that can become magnified when
it is the physician who reviews the con-
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“finds and documents” four conditions
(See Table 3). The first point is easily
satisfied by the acute nature of prehospital illness, qualification of those applying
1. The research
could not practicably
be carried out without the waiver.
2. Whenever
appropriate,
the subject will be provided
with additional,
pertinent
inforthe consent and the time constraints es
mation after participation.
sentially preventing traditional consent.
3. The research
involves no more than minimal risk.
Many therapies are also time-depen4. The waiver will not affect adversely
the rights and welfare of the subject.
dent. Point two presents little problem
and point four must be addressed by ensuring any preference of the patient is
Food and Drug Administration
strictly honored, such as an advance diConsent Waiver Requirements
rective.
The most difficult and complex idea
1. Subject is confronted
by a life-threatening
situation,
necessitating
the experimental
involves the “condition of minimal risk.”
therapy.
2. Informed
consent
cannot be obtained
from the subject due to an inability to commuMinimal risk is defined as the risk of
nicate or obtain legally effective consent
from the subject.
harm anticipated in the proposed re3. Insufficient
time to obtain consent
from the subject’s
legal representative.
search not being greater than those or4. There is no reliable alternative
method of approval
therapy that provides
an equal or
dinarily encountered in daily life or
greater likelihood of saving the life of the subject.
during the performance of routine physical or psychological exams or tests.
sent. However, unlike a normal busi- how it is accepted by patients, has Thus, the experimental therapy should
ness contract in which the burden of demonstrated that research subjects of- not entail more than this additional risk
understanding is on the consumer, here ten do not understand the process, and when compared to standard therapy.
the responsibility
lies with the re- may sign the form for such reasons as This definition has limited utility, as
searcher. Imagine if when you purchase believing it necessary to receive treat- many of the disease processes studied
a car, the dealer was required to inform
ment, or to please the researcher.8
in the prehospital setting, especially in
you of all the possible faults of the auto. When they do understand the purpose, air medical transport, (such as cardiac
This is the situation with research.
they often prefer to have the decision arrest, trauma and shock) inherently
The next process is the actual admin- made by the physician. In the prehospi- have poor outcome regardless of the
istration of the consent, which is also tal setting, practical considerations limit therapy applied.
well-defined.7 The first step is inform- the utility of traditional informed conThe second set of waiver regulations
ing. This is a detailed 16-step process sent. First, the process is lengthy and is provided through the FDA and govthat dictates the key elements of infor- time consuming. Second, it requires a ems research on unapproved drugs and
mation that must be communicated to competent and understanding patient
devices (Table 4). Points one through
the subject. While each step is not valid and a qualitied person to administer the three are usually easily satisfied, while
for every project, the basic framework
consent (usually a physician). Obviously, point four may present problems. If any
must be followed. Next is an assessment these requirements would exclude the physician feels certain that one therapy
of the subject’s comprehension of the majority of patients and, therefore, most is superior, he or she is permitted
presented material, and proof of under- EMS research. A directive, issued in (some would say ethically bound) to
1993 by the OPRR, mandates that all hu- use this therapy. Therefore, some have
standing may be required. Interestingly,
man studies approved by an IRH require objected to the randomization process,
the material needs only to be understood at the time of presentation, not in prospective informed consent from the in which a patient cannot predict which
the future. Following this, an assess- patient or patient representative. In re- therapy he or she will receive. In such
ment of the subject’s autonomy must be sponse to the acknowledged hardship on
cases, there must be a real question
conducted, and he or she must not be emergency research, a meeting has about which treatment is superior, reunder any undue stress. The last step is been convened by the Food and Drug gardless of individual opinion. History
Administration (FDA) and the National has shown the need for objective rethe demonstration by the prospective
participant of a willingness to partici- Institutes of Health to obtain public and search studies, despite anecdotal expepate, which forms the actual act of con- scientitic input on the impact of consent rience and opinions to be contrary.
senting. In the majority of cases, this regulations on emergency research.
Even when there is thought to be a
Until these issues are resolved, waiver “clear” advantage to a particular therincludes the completion of a written
form with a signature, although other regulations exist.
apy, in as many as 50% of cases this
There are two sets of waiver regula- preference has proven incorrect when
methods may be acceptable.
each issued by the De- formally studied.2
There are a number of problems with tions-one
the classical approach to consent, partic- partment of Health and Human Services
There also has been significant disularly in the prehospital setting. Re- (DHSS), the other by the FDA.2 The cussion about the concept of deferred
search into the consent procedures, and first (DHSS) permits a waiver if the IRB consent.3 This has been used in the set-

Department
of Health and Human Services
Consent Waiver Requirements
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ting of resuscitation research in which
the patient is enrolled into the study
without approval from the subject or
family. Once the subject is stabilized
and the initial experimental therapy initiated, the family is approached for traditional informed consent. At that point,
the family may choose to discontinue
the experimental treatment. This alternative is currently not an option as determined in the 1993 OPRR directive.
This leaves only two options: informed
consent or waiver.
In light of the traditional waiver requirement and the changing ideas and
concerns surrounding consent, the FDA
has put forth a new set of proposed
guidelines titled, “Exception from
Informed Consent for Emergency
Research.“10 This both condenses and
expands on the previous two waiver regulations (Iable 5). There must be a real
question about current therapy, and
valid scientific evidence, which may include that obtained through randomized
trials, should be necessary to determine
which intervention is most beneficial. No
practical way can exist to obtain informed consent at the time of intervention, and prospective obtainment of
consent is not feasible because the emergence of the condition being studied cannot be predicted reliably in particular
individuals. The risk must be determined to be reasonable in light of what is
known about the medical condition and
the risks and benefits of both the current
and interventional
therapy. The increased provision for public disclosure
and involvement makes the researchers
responsible to the community in which
the research is being performed and also
provides input from a viewpoint that may
not be considered routinely during pro
posal development. Consultation may be
initiated by the IRB. Finally, although

Proposed Food and Drug Administration
Exceptions to Consent
1.

2.

Life-threatening
situation
a. Available treatment
unproven
b. Valid evidence
that supports

or unsatisfactory
proposed
study

Obtaining
valid informed
consent
not feasible
a. Medical condition
precludes
consent
b. Intervention
must be administered
before representative
c. Prospective
identification
of subjects
is not possible

3.

Opportunity
for subjects
to participate
a. Life-threatening
situation necessitates
b. Risk is reasonable

4.

Research

5.

Additional
protection
of rights and welfare will be provided
a. Consultation
from community
representatives
b. Public disclosure
prior to study of risks and benefits
c. Public disclosure
following study
d. Development
of independent
data and safety monitoring

6.

could

not be carried

International
Review Board
which it may be appropriate.

is in their best
intervention

out without

reviews

can be obtained

interest

waiver

and approves

the traditional informed consent has
been waived, all subjects (if not incapacitated) or their authorized representatives must be informed of their inclusion
into the study, and of the details of the
study. All subjects also must be informed
that they may discontinue their participation at any time.
Despite the safeguards imposed by
the IRB and the consent process, the
prospective researcher still may have
problems with ethical considerations.
There are many motives for performing
clinical research, which run the gamut
from patient-care concerns, such as inadequate standard therapy, to those
less pure, such as reimbursement and
academic standing. Despite the best intentions of the researcher, studies have
shown that a trial sponsored by a party
with a direct stake or interest in the outcome (such as a drug company or a device manufacturer) may influence the
conclusion, even if done unconscious-

consent

informed

board
consent

for situations

for

ly.11 Strict attention to this possibility,
such as effective blinding of subjects
and researchers and use of objective
data points, will help to minimize the
problem. In addition, if the researcher
has any financial or other outside interest in the trial, this must be mentioned
in the paper.f2
It is imperative that the rights and
welfare of study populations be observed and guarded strictly. In the air
medical transport environment, this
means that all studies must be reviewed
by an appropriate IRB prior to initiation
of the study. Most IRBs are willing to
work with the researcher to improve the
proposal and to address ethical and consent issues without preventing the proposed research. The IRB processes of
approval and informed consent help to
ensure maintenance of the subject’s
rights and help to protect the researcher
from claims of human rights violations.
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